BACKGROUND/AIMS: Serum high sensitivity C-reactive protein (hs-CRP) is a surrogate marker for cardiovascular disease risks and related mortality. However, the features of hs-CRP in chronic HCV infection (CHC) patients have not been fully addressed. This study aimed to elucidate the characteristics of hs-CRP and its correlation with clinical profiles in CHC patients. METHODS: Ninety-five CHC patients and 95 age- and sex-matched healthy controls were enrolled for serum hs-CRP level, biochemical, and metabolic profiles examinations. Sequential changes of hs-CRP levels in CHC patients receiving peginterferon/ribavirin combination therapy were also evaluated. RESULTS: The mean hs-CRP level of CHC patients was significantly higher than that of healthy controls (0.97 ± 0.11 vs. 0.24 ± 0.07 mg/L, P < 0.001). There was no significant correlation between hs-CRP and both virological and histological factors. CHC patients with a high LDL-C level had significantly higher mean hs-CRP (1.38 ± 0.20 mg/L) than that of patients without (0.59 ± 0.06 mg/L) (P < 0.001). Hs-CRP level was significantly decreased in 83 patients after peginterferon/ribavirin combination therapy (0.24 vs. 0.62 mg/L, P < 0.001), particularly in 68 patients achieving a sustained virological response (0.25 vs. 0.64 mg/L, P < 0.001). CONCLUSION: CHC patients had a higher hs-CRP level than healthy controls which could be ameliorated after peginterferon/ribavirin combination therapy.
BACKGROUND/AIMS: Serum high sensitivity C-reactive protein (hs-CRP) is a surrogate marker for cardiovascular disease risks and related mortality. However, the features of hs-CRP in chronic HCV infection (CHC) patients have not been fully addressed. This study aimed to elucidate the characteristics of hs-CRP and its correlation with clinical profiles in CHCpatients. METHODS: Ninety-five CHCpatients and 95 age- and sex-matched healthy controls were enrolled for serum hs-CRP level, biochemical, and metabolic profiles examinations. Sequential changes of hs-CRP levels in CHCpatients receiving peginterferon/ribavirin combination therapy were also evaluated. RESULTS: The mean hs-CRP level of CHCpatients was significantly higher than that of healthy controls (0.97 ± 0.11 vs. 0.24 ± 0.07 mg/L, P < 0.001). There was no significant correlation between hs-CRP and both virological and histological factors. CHCpatients with a high LDL-C level had significantly higher mean hs-CRP (1.38 ± 0.20 mg/L) than that of patients without (0.59 ± 0.06 mg/L) (P < 0.001). Hs-CRP level was significantly decreased in 83 patients after peginterferon/ribavirin combination therapy (0.24 vs. 0.62 mg/L, P < 0.001), particularly in 68 patients achieving a sustained virological response (0.25 vs. 0.64 mg/L, P < 0.001). CONCLUSION:CHCpatients had a higher hs-CRP level than healthy controls which could be ameliorated after peginterferon/ribavirin combination therapy.
Entities:
Keywords:
Antiviral therapy; Hepatitis C virus; High sensitivity C-reactive protein
Authors: C Mazzaro; G Panarello; F Tesio; G Santini; M Crovatto; G Mazzi; F Zorat; P Tulissi; E Pussini; S Baracetti; L Campanacci; G Pozzato Journal: J Intern Med Date: 2000-05 Impact factor: 8.989
Authors: Jason Reingold; Christine Wanke; Donald Kotler; Cora Lewis; Russell Tracy; Steven Heymsfield; Phyllis Tien; Peter Bacchetti; Rebecca Scherzer; Carl Grunfeld; Michael Shlipak Journal: J Acquir Immune Defic Syndr Date: 2008-06-01 Impact factor: 3.731
Authors: M Yoneda; S Saito; T Ikeda; K Fujita; H Mawatari; H Kirikoshi; M Inamori; Y Nozaki; T Akiyama; H Takahashi; Y Abe; K Kubota; T Iwasaki; Y Terauchi; S Togo; A Nakajima Journal: J Viral Hepat Date: 2007-09 Impact factor: 3.728
Authors: Jean Jeudy; Pratik Patel; Nivya George; Shana Burrowes; Jennifer Husson; Joel Chua; Lora Conn; Robert G Weiss; Shashwatee Bagchi Journal: AIDS Date: 2022-03-01 Impact factor: 4.177
Authors: Danielle Gonçalves; Claudia Lima; Paula Ferreira; Paulo Costa; Angela Costa; Walter Figueiredo; Thais Cesar Journal: Food Nutr Res Date: 2017-03-22 Impact factor: 3.894
Authors: Ahmed Abdul-Abbas Bayram; Hussein O M Al-Dahmoshi; Noor S K Al-Khafaji; Raheem Tuama Obayes Al Mammori; Ali Husain Shilib Al-Shimmery; Morteza Saki Journal: Biomedicine (Taipei) Date: 2021-12-01